Docoh
Loading...

EMH Emerald Health Therapeutics

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month ofApril 2020

 

Commission File Number:333-229744

 

EMERALD HEALTH THERAPEUTICS, INC.
(Translation of registrant's name into English)

 

210 – 800 West Pender Street

Vancouver, British Columbia V6C 1J8

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

☐ Form 20-F   ☒ Form 40-F

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

On April 29, 2020, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

(c) Exhibit 99.1. Press release dated April 29, 2020

 

1

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

      Emerald Health Therapeutics, Inc.     
  (Registrant)
   
Date: April 29, 2020     /s/ Dr. Avtar Dhillon    
  Avtar Dhillon
  Executive Chairman

 

 

2